Skip to main content
Fate gains FDA's OK to initiate trial for blood cancer cell therapy

The investigational new drug application submitted by Fate Therapeutics for its off-the-shelf stem cell therapy FT516 to treat hematologic cancers has been accepted by the FDA. An early-stage trial will be launched to evaluate the therapy's safety and tolerability, and patients with treatment-resistant blood disorders will be administered three weekly doses.

Full Story: